Linfoma de Hodgkin con compromiso hepático tratado con esquema gemcitabina, dexametasona y cisplatino como puente para terapia estándar: Caso clínico / Hodgkin lymphoma with hepatic involvement treated with dexametasone, gemcitabine and cisplatin as a bridge to standard therapy: Report of one case
Rev. méd. Chile
;
140(7): 902-905, jul. 2012. ilus
Article
in Spanish
| LILACS
| ID: lil-656362
ABSTRACT
Background:
The initial presentation of Hodgkin lymphoma with liver involvement is rare. In these patients, the standard first-line therapy with ABVD (Adriamycin, Bleomycine, Vinblastine, Dacarbazine) imply an additional risk for liver toxicity. We report a 64-year-old woman who presented with jaundice, choluria, malaise and weight loss. In the initial evaluation she had jaundice and palpable groin lymph nodes. An obstructive biliary disease was ruled out with magnetic resonance imaging studies. A lymph node biopsy showed a Hodgkins lymphoma, Mixed-cellularity subtype. Considering the liver dysfunction, an alternative scheme of chemotherapy with dexamethasone, gemcitabine and cisplatin (GDP) was administered. After 4 cycles, a significant improvement in liver hepatic function tests was reached and a conventional chemotherapy (ABVD) was begun. While the literature provides some low toxicity protocols for patients with liver involvement, favorable results of our clinical case report allows us to postulate GDP as an alternative for salvage therapy in these patients.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Hodgkin Disease
/
Antineoplastic Combined Chemotherapy Protocols
/
Liver Diseases
Type of study:
Practice guideline
Limits:
Female
/
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2012
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Hospital Regional de Talca/CL
/
Universidad Católica del Maule/CL
Similar
MEDLINE
...
LILACS
LIS